PET Scan Misses Cutaneous Melanoma Metastasis with Significant Tumour Size and Tumour Thickness

Georgi Tchernev1,2*, Liubomira Victor Popova1

1Department of Dermatology, Venereology and Dermatologic surgery, Medical Institute of Ministry of Interior (MVR-Sofia), General Skobelev 79, 1606, Sofia, Bulgaria; 2Onkoderma - Polyclinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria

Citation: Tchernev G, Popova LV. PET Scan Misses Cutaneous Melanoma Metastasis with Significant Tumour Size and Tumour Thickness. Open Access Maced J Med Sci. 2017; Aug 19; 5(3):608-612. https://doi.org/10.3889/oamjms.2017.221

Abstract

BACKGROUND: Although PET-scan is an advanced, innovative and widely used method for monitoring patients with different types of cancer diseases, it is important to note that its application in patients with cutaneous melanoma is limited and should be reconsidered.

CASE REPORT: To affirm this new statement, we are presenting a case from our clinical practice of a patient with melanoma of the interdigital space (with resected in sano primary melanoma and performed complete lymphadenectomy) that showed locoregional and systemic progression in two months post operation. The PET scan performed within the second hospitalization (and before the second operation) did not detect the presence of any cutaneous metastases, which were clinically and histologically verified after the second operative procedure.

CONCLUSIONS: This data suggests that PET scan may not be able to detect the presence of cutaneous melanoma metastases. Having in mind that our patient has been operated twice in the area of the primary lesion (as the surgical wound underwent secondary healing), theoretically, the abundant cicatrization could have led to reduced glucose uptake in the surrounding cancerous tissue. Monitoring of a larger number of patients with locoregional metastases and surgical interventions in different locations would shed light on the observations shared by us.

Introduction

Positron emission tomography (PET) is a non-invasive nuclear imaging technique with an incomparable ability to assess functional and biochemical processes in tissues [1]. Due to its high sensitivity and specificity, it has a wide application in oncology for cancer diagnosis, staging, restaging, detection of the extent of local and regional disease spread, as well as in the monitoring of response to cancer treatment [2]. An important feature of PET is its ability to detect the earliest stages of many diseases due to its possibility to assess the biochemical and functional processes in tissues. This great advantage of PET explains the importance of the method to the clinical oncology practice [3]. It is important to emphasise that this characteristic significantly differs it from other high sensitivity methods like MRI (magnetic resonance imaging) and CT (computer tomography), which detect only anatomical or functional changes that have already occurred [4].

Specifically, about melanoma malignum, FDG-PET takes an important place in its detection and imaging [5].

Case report

A 58-year-old male patient presented to the...
department of dermatologic surgery because of the dark lesion on his right foot. Clinical examination revealed a dark brown to black pigmented macula, located in the interdigital space between the first and the second finger of the right foot, with uneven distribution of colour and irregular borders. The lesion was removed by surgical excision under local anaesthesia, with 0.5 cm field of safety margins in all directions. Also, a lymph node dissection under general anaesthesia was performed with retroperitoneal entrance toward the iliac and femoral vessels. Intraoperatively were established dark coloured packages of enlarged lymph nodes with a firm texture and a diameter of 2.5 cm. Enlarged lymph nodes were observed in the obturator whole, with the same characteristic. A lymph node was found in the pelvis immediately adjacent to the v. iliaca externa, infiltrated the vein wall. Radical lymph dissection was performed in a femoral, obturator and para iliac area. 

Histological examination of the cutaneous lesion revealed moderately atypical cells with vesiculous nuclei, suspicious for melanoma, with tumour thickness 2 mm (Breslow).

Histological examination of the dissected lymph nodes verified total and non-total metastasis from melanoma, some with capsular infiltration, some of them without.

The patient was diagnosed in stage IIIC and referred for a PET-scan in 2 months. Two months later the patient presented to the department with two pigmented lesions with uneven borders in the same location (Fig. 1a).

Preoperatively, PET-scan examination was performed, and it detected one right prevertebral lymph node (L3), measured 10mm with SUVmax 3.2; three enlarged paraaortic lymph nodes at the level of the bifurcation, measured up to 13 x 6 mm with SUVmax up to 4.9; and distal right parailiac lymph nodes, measured up to 17 x 10 mm with SUVmax 10.0. Infiltrative, probably inflammatory parenchymal changes of the right lung in the interlobe and para cardiac with SUVmax up to 2.6 were also observed. However, no cutaneous metastases were detected on the PET-scan.

The cutaneous lesions were removed by surgical excisions, and the histological examination verified nodular melanoma malignum 1cm in diameter, with no ulceration; mitoses 1-2; Clark II-III; Breslow – 2.

By the clinical results, a restaging is performed in stage IV. The patient was referred for therapy with Pembrolizumab (KEYTRUDA) after hospitalisation in the oncology department.

Discussion

Nowadays, malignant melanoma is showing a tendency to increase in incidence – since 1970 it has approximately doubled with an estimated 68,720 new diagnosed in 2009 [6]. Early stages of melanoma are effectively treated with surgical excision [7]. However, by the time of diagnosis 15% of patients are presented with metastases or locally advanced tumor process [8].

FDG-PET has a wide application in oncology because of its significant role in cancer diagnosis, staging, restaging and therapeutic response monitoring in the most common cancers [9]. FDG (fluorodeoxyglucose) is an analog of glucose used as a radiotracer in order to detect tumor cells which are distinguished to have elevated glucose uptake [10]. It is a well-known fact that tumor cells have high metabolic needs of glucose, lipids and amino acids. PET imaging is based exactly on this distinctive feature of tumors, which explains the high sensitivity and specificity of the method when it refers to cancer diagnosis, staging and therapeutic response monitoring [11]. Glucose, as well as oxygen, growth factors and nutrients are critical factors that ensure the progress of cancer cells into solid tumors by activating their specific metabolic pathways [12]. Microenvironment, especially hypoxia takes important role in the evolution of tumors [13]. In hypoxic conditions of 100-150 μm distance between the tumor cells and the nearest blood vessel, their ability to endure profound hypoxia is condition for their progress [14]. An adapting mechanism of cancerous
cells is the ability to rely on anaerobic glucose metabolism, which ensures the major needs of energy for tumour growing [15].

Nowadays, PET takes a significant place in oncology where it is widely used for cancer diagnostic, staging and therapy response monitoring [16]. Soon, in 1998, the limitations of PET were overcome with the development of the first combined PET/CT, firstly installed in University of Pittsburgh Medical Center [17]. This imaging technique provides an assessment of both biochemical and anatomic characteristics of tissues and is a significant advance in the evaluation of primary tumours, metastases, staging, therapy response monitoring and post-treatment recidives [18].

FDG-PET has a large application in evaluation of the extent of local and regional disease spread [19, 20]. Results of a meta-analysis evaluating the ability of PET in staging and restaging of cutaneous melanoma confirmed its usefulness in the detection of distant metastases. However, not so desirable results were observed in the evaluation accuracy of regional metastases as it does not detect microscopic disease [21]. Another report of Crippa et al. affirms reliable sensitivity and specificity in detection of lymph node metastases in patients with malignant melanoma. The presented results are showing that FDG-PET detected 100% of metastases ≥10 mm, 83% of metastases 6-10 mm, and 23% of metastases ≤ 5 mm. It is important to emphasise that the FDG-PET had high sensitivity (> or = 93%) only for metastases with more than 50% lymph node involvement or with capsular infiltration. However, this imaging method is not sensitive enough to detect subclinical microscopic disease [22]. The fact that PET sensitivity for melanoma lymph node metastases is dependent on tumour volume is also reported in data presented by Wagner et al. [23].

However, despite the successful results of PET in cancer diagnosis and evaluation, it has some important limitations that should not be neglected: (1) no quantitative system in assessing changes in FDG-metabolism in the therapeutic response. In the USA the development of such system is based on PET Response Criteria in Solid Tumors (PERCIST) [24]; (2) False-positive results. False positive results are possible because of increased FDG uptake in some normal body areas, such as lymphoid tissue and brown adipose tissue [25]. Another reason for false positive results may be the increased accumulation of FDG in some benign processes as inflammation or infection [26]; (3) low sensitivity. Low sensitivity may be observed in hypocellular cancers such as desmoplastic or mucinous tumours, as well as in micrometastases in breast cancer and melanoma [27]. Also, PET presents low sensitivity in well-differentiated low-grade tumours, which have lower glucose uptake, such as carcinoid tumours, renal cell carcinoma, bronchoalveolar-cell carcinoma and most prostate cancers [28].

We present a case of a patient with a malignant melanoma where two satellite cutaneous metastases measured 2 x 0.7 cm were not detected via PET-scan examination. With the presented case we want to report the unreliable results of PET-imaging when it refers to cutaneous melanoma metastases.

References

1. Verboom P, van Tinteren H, Hoekstra OS, et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging. 2003;30(11):1444–9. https://doi.org/10.1007/s00259-003-1199-9 PMid:14579081

2. Rohren EM, Tunkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231(2):305–32. https://doi.org/10.1148/radiol.231201185 PMid:15044750

3. Peter Oehr,Hans-Jürgen Biersack, R. Edward Coleman. PET and PET-CT in Oncology. Springer Science & Business Media, 6.12.2012

4. McGeer PL, Kamo H, Harrop R, McGeer EG, Martin WR, Pate BD, Li DK. Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease. Neurology. 1986;36(12):1569-74. https://doi.org/10.1212/WNL.36.12.1569 PMid:3491344

5. Gellén E, Sántha O, Janka E, Juhasz I, Peiter Z, Erdiei I, Lukacs R, Fedinecz N, Galuska, L., Remenyik E, Emri G. Diagnostic accuracy of 18F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma. J Eur Acad Dermatol Venereol, 2015; 29: 1938–1944. https://doi.org/10.1111/jdv.13084 PMid:25753249

6. Mun G-H. Management of Malignant Melanoma. Archives of Plastic Surgery. 2012;39(5):565-574. https://doi.org/10.5999/aps.2012.39.5.565 PMid:23094257 PMCID:PMC3474418

7. Kimbrough CW, McMasters KM, Davis EG. Principles of Surgical Treatment of Malignant Melanoma. 2014; 94(5):973-88.

8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. https://doi.org/10.3322/caac.20006 PMid:19473485

9. Fletcher JW, Djalbogovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Garman M, Shields AF. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49(3):480-508. https://doi.org/10.2967/jnumed.107.047787 PMid:18287273

10. Khan N, Islam MM, Mahmood S, Hossain GA, Chakraborty RK, 18F-fluorodeoxyglucose uptake in the tumor. Mymensinhg Med J. 2011;20(2):332-42. PMid:21522112

11. Zhu A, Lee D, Shim H. Metabolic PET Imaging in Cancer Detection and Therapy Response. Seminars in oncology. 2011:38(1):55-69. https://doi.org/10.1053/j.seminoncol.2011.01.012 PMid:21362516 PMCID:PMC3075495

12. Casciari JJ, Sotichos SV, Sutherland RM. Variations in tumor cell growth rates and metabolism with oxygen concentration, glucoseconcentration, and extracellular pH. J Cell Physiol. 1992;151(2):386-94. https://doi.org/10.1002/jcp.1041510220 PMid:1572910

13. Xiao-Feng Li,Yang Du,Yuanyuan Ma, Gregory C, Postel A, Civelek C. 18F-Fluorodeoxyglucose Uptake and Tumor Hypoxia:
Revisit 18F-Fluorodeoxyglucose in Oncology Application. Transl Oncol. 2014; 7(2): 240–247. https://doi.org/10.1016/j.tranon.2014.02.010 PMid:24699008 PMcid:PMC4101348

14. Fenton BM, Paoni SF, Beauchamp BK, Ding I. Zonal image analysis of tumour vascular perfusion, hypoxia, and necrosis. British Journal of Cancer. 2002;86(11):1931-1936. https://doi.org/10.1038/sj.bjc.6600343 PMid:12087474 PMcid:PMC2375413

15. Kim Y, Lin Q, Glazer PM, Yun Z. Hypoxic Tumor Microenvironment and Cancer Cell Differentiation. Current Molecular Medicine. 2009;9(4):425–434. https://doi.org/10.2174/156652409788167113 PMid:19519400 PMcid:PMC2375413

16. Sai KK, Zachar Z, Bingham PM, Mintz A. Metabolic PET Imaging in Oncology. American Journal of Roentgenology. 2017;1-7. https://doi.org/10.2214/AJR.17.18112

17. Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol. 2002;75 (Spec No):S24-30. https://doi.org/10.1259/bjr.75.suppl_9.750024 PMid:12519732

18. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242(2):360–85. https://doi.org/10.1148/radiol.2422051113 PMid:17255408

19. Mansour AA, Kelley MC, Hatmaker AR, Holt GE, Schwartz HS. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging. Annals of Surgical Oncology. 2010;17(4):1144–51. https://doi.org/10.1245/s10434-009-0843-4 PMid:19967460

20. Strobel K, Dummer R, Husarik DB, Perez Lago M, Hany TF, Steiner HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology. 2007;244(2):566–74. https://doi.org/10.1148/radiol.2442061099 PMid:17641374

21. Jimenez-Requena F, Delgado-Bolton RC, Fernandez-Perez C, et al. Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging. 2010;37(2):284–300. https://doi.org/10.1007/s00259-009-1224-8 PMid:19727717

22. Cripta F, Leutner M, Belli F, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med. 2000;41(9):1491–4. PMid:10994727

23. Wagner JD, Schauwecker DS, Davidson D, Wencs S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol. 2001;77(4):237–42. https://doi.org/10.1002/jso.1102 PMid:11473371

24. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354(5):496–507. https://doi.org/10.1056/NEJMra050276 PMid:16452561

25. Chang JM, Lee HJ, Goo JM, et al. False Positive and False Negative FDG-PET Scans in Various Thoracic Diseases. Korean Journal of Radiology. 2006;7(1):57-69. https://doi.org/10.3348/kjr.2006.7.1.57 PMid:16549957 PMcid:PMC2667579

26. Long NM, Smith CS. Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging. Insights into Imaging. 2011;2(6):679-698. https://doi.org/10.1007/s13244-010-0062-3 PMid:22347986 PMcid:PMC3259390

27. Challapalli A, Abogaya EO. Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring. Frontiers in Oncology. 2016;6:44. https://doi.org/10.3389/fonc.2016.00044 PMid:26973812 PMcid:PMC4770188

28. Taci E, Ozmen O, Gokcek A, et al. 18F-FDG PET/CT rarely provides additional information other than primary tumor detection in patients with pulmonary carcinoid tumors. Annals of Thoracic Medicine. 2014;9(4):227-231. https://doi.org/10.4103/1817-1737.140134 PMid:25276242 PMcid:PMC4166070